MDT

February 5, 2012

Biotech Deal Activity Declines…The Pause that Refreshes?

January 14, 2010 By MD Becker Partners 1 Comment

2160996-small

* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the [...]

Filed Under: Articles Tagged With: 2010 outlook, Akorn, AKRX, Amgen, AMGN, AnaptysBio, AstraZeneca, AZN, Bayer, BioLeap, biotechnology, BMY, Bristol-Myers Squibb Company, Cell Therapeutics, CEPH, Cephalon, Ception Therapeutics, Chiral Quest, CrystalGenomics, CTIC, CYCC, Cyclacel Pharmaceuticals, ENMD, EntreMed, FORMA Therapeutics, GDNF, glial cell line-derived neurotrophic factor, JP Morgan Healthcare Conference, KaloBios Pharmaceuticals, life sciences, MDCO, MDT, MedGenesis Therapeutix, Medicines Company, Medtronic, Novartis AG, NUVA, NuVasive, NVS, Peptimmune, Progentix Orthobiology, protein-protein interactions, Proteus Biomedical, roche, Rosetta Genomics, ROSG, Sanofi-Aventis, SNGX.OB, SNY, Soligenix, Trillium therapeutics, VentiRx Pharma, ZGEN, ZymoGenetics

Treating Parkinson’s Disease: Investment Opportunities and Challenges

August 2, 2009 By MD Becker Partners 6 Comments

Parkinson’s disease [PD] is one of the most common of the neurogenerative diseases affecting 1 in 100 people over the age of 60. Approximately 1.5 million Americans currently suffer from the disease and it is estimated that 60,000 Americans are newly diagnosed each year. PD is both a chronic and progressive disease. While the precise [...]

Filed Under: Articles Tagged With: AAV, Addex Pharmaceuticals, adeno-associated virus, Amgen, AMGN, Amicus Therapeutics, Amsterdam Molecular Therapeutics, AVGN, Avigen, BDNF, CERE-120, Ceregene, CNS Protein Therapeutics, deep brain stimulation, DEPO, Depomed, dopamine, dopaminergic neurons, FOLD, GDNF, gene therapy, GENZ, Genzyme Corporation, glutamic acid decarboxylase, Impax Pharmaceuticals, Inc., IPX066, IPXL, L-dopa, LentiVector, levodopa, MANF, MDT, Medtronic, mesencephalic astrocyte-derived neurotrophic factor, Neurogen Corporation, Neurologix, neurotrophic factors, neurturin, NLX-P101, NRGN, NRGX, Oxford BioMedica, Parkinson's disease, PRAN, Prana Biotechnology, ProSavin, SynchoMed, Synergen, Unified Parkinson’s Disease Rating Scale